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Background: Reduced bioactive vascular endothelial growth factor (VEGF) has been demonstrated in
several inflammatory lung conditions including the acute respiratory distress syndrome (ARDS). sVEGFR-1,
a soluble form of VEGF-1 receptor, is a potent natural inhibitor of VEGF. We hypothesised that sVEGFR-1
plays an important role in the regulation of the bioactivity of VEGF within the lung in patients with ARDS.
Methods: Forty one patients with ARDS, 12 at risk of developing ARDS, and 16 normal controls were
studied. Bioactive VEGF, total VEGF, and sVEGFR-1 were measured by ELISA in plasma and
bronchoalveolar lavage (BAL) fluid. Reverse transcriptase polymerase chain reaction for sVEGFR-1 was
performed on BAL cells.
Results: sVEGFR-1 was detectable in the BAL fluid of 48% (20/41) of patients with early ARDS (1.4–
54.8 ng/ml epithelial lining fluid (ELF)) compared with 8% (1/12) at risk patients (p = 0.017) and none of
the normal controls (p = 0.002). By day 4 sVEGFR-1 was detectable in only 2/18 ARDS patients
(p = 0.008). Patients with detectable sVEGFR-1 had lower ELF median (IQR) levels of bioactive VEGF than
those without detectable sVEGFR-1 (1415.2 (474.9–3192) pg/ml v 4761 (1349–7596.6) pg/ml, median
difference 3346 pg/ml (95% CI 305.1 to 14711.9), p = 0.016), but there was no difference in total VEGF
levels. BAL cells expressed mRNA for sVEGFR-1 and produced sVEGFR-1 protein which increased
following incubation with tumour necrosis factor a.
Conclusion: This study shows for the first time the presence of sVEGFR-1 in the BAL fluid of patients with
ARDS. This may explain the presence of reduced bioactive VEGF in patients early in the course of ARDS.
I
n order to preserve gas exchange, the lung needs a
confluent layer of alveolar epithelial and endothelial cells
to prevent flooding of the alveolar space with fluid and
plasma proteins. When this layer is damaged the resultant
non-cardiogenic pulmonary oedema leads to refractory
hypoxia and the need for mechanical ventilation. Vascular
endothelial growth factor (VEGF) plays a central role in
embryonic pulmonary angiogenesis and development.1 In
human fetuses at term, low alveolar levels of VEGF are
associated with the development of a severe respiratory
distress syndrome.2 As the lung develops VEGF protein levels
within the alveolus increase such that, by adulthood, the
epithelial lining fluid (ELF) of normal adults has 11 ng/ml of
VEGF protein.2 This is 500 times higher than the average
plasma level.2 In this regard the lung is almost unique, since
most tissues express much lower levels of VEGF. In situ
hybridisation has shown that the major sources of VEGF in
the lung are mesenchymal and type II alveolar cells.2 During
acute inflammation alveolar macrophages and neutrophils
may also play a role in VEGF production.3
The function and regulation of VEGF in acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS) is
complex. VEGF is a potent endothelial cell mitogen and
permeability factor. Clinical studies have reported increased
plasma VEGF levels in a wide variety of inflammatory
conditions where increased capillary permeability is a feature
such as pre-eclampsia,4 inflammatory pleural effusion,5 and
ARDS.6 In vitro studies using plasma from patients with
ARDS showed that the addition of a specific antagonist to
VEGF can reduce endothelial monolayer permeability by up
to 50%, suggesting an important role for VEGF in regulating
alveolar-capillary permeability in ARDS.6 In contrast to the
plasma compartment, however, bioactive VEGF is reduced in
the ELF of patients with pulmonary fibrosis,7 emphysema,8
sarcoidosis,7 following lung transplantation,9 and ARDS.10 11
Furthermore, in ARDS the early restoration of ELF VEGF
levels was associated with recovery from lung injury.10 It has
been suggested that VEGF within the lung may therefore play
a dual role, not only in contributing to the regulation of
alveolar-capillary permeability but also promoting lung
repair.3 This hypothesis is supported by recent in vitro studies
that have shown that VEGF can enhance alveolar cell
proliferation after acid injury12 and increase surfactant
production from type II cells.1
The mechanisms responsible for regulating VEGF in the
lung are currently unclear. Several hypotheses have been
proposed to explain the low intrapulmonary levels of VEGF.
These include decreased production due to the loss of alveolar
type II cells, increased degradation of VEGF by proteases
released from neutrophils and other inflammatory cells, or
increased release of VEGF from the lung to the plasma as a
consequence of damage to the alveolar-capillary barrier.3 The
recent discovery of specific and non-specific cytokine
antagonists in patients with ARDS has considerably
enhanced our understanding of the complex regulation of
the biological effects of proinflammatory cytokines within
the alveolar space in ARDS.13
We hypothesised that the presence of an antagonist to
VEGF in BAL fluid may be important in regulating the
bioactivity of VEGF. Soluble VEGFR-1 (sVEGFR-1) is a splice
variant of the membrane bound VEGF receptor VEGFR-1.14 It
was initially isolated from human umbilical vein endothelial
cells and is secreted from monocytes, myocytes, and placental
tissue. sVEGFR-1 contains the ligand binding domain of the
membrane bound receptor and is a potent antagonist of
bioactive VEGF.15 sVEGFR-1 regulates the bioactivity of VEGF
Abbreviations: ALI, acute lung injury; ARDS, acute respiratory distress
syndrome; ELF, epithelial lining fluid; LIS, lung injury score; TNFa,
tumour necrosis factor a; VEGF, vascular endothelial growth factor
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function by forming heterodimers with it which prevent
binding and activation of the VEGF receptors.16
We hypothesised that the reduced bioactive VEGF found in
patients with ARDS might be due to the presence of sVEGFR-
1. To examine this hypothesis we measured sVEGFR-1 and
total VEGF and, as in previous studies, bioactive VEGF in the
BAL fluid of patients at risk for ARDS and those with
established ARDS. Our second goal was to investigate the
relationship between these measures and indices of the
severity of lung injury and clinical outcome in patients with
established ARDS.
METHODS
Subjects
Patients were studied within 48 hours of admission to the
intensive care units of Birmingham Heartlands Hospital
(Birmingham, UK) and Southmead Hospital (Bristol, UK)
between 2001 and 2003. The study was approved by the local
research and ethics committees at each institution.
Patients were identified as having ALI or ARDS according
to the American-European consensus statement.17 Patients
who did not fulfil these criteria but had predisposing risk
factors for ARDS were defined as ‘‘at risk’’. Patients were
ventilated using pressure controlled ventilation aiming for
tidal volumes of 6 ml/kg. Age/sex matched health volunteers
(non-smoking, free from respiratory disease) were defined as
normal. Bronchoscopy and bronchoalveolar lavage (BAL) was
performed in all patients immediately following inclusion
and, when possible, 4 days later. The Acute Physiology and
Chronic Health Evaluation (APACHE) II score18 and
Simplified Acute Physiology Score (SAPS) II19 were calculated
as a global assessment of the severity of illness in each group.
Murray lung injury score (LIS) and PaO2 to FiO2 ratio
20 were
calculated as a measure of the severity of lung injury.
Bronchoscopy
Briefly, the bronchoscope was wedged into to a subsegmental
bronchus in the middle lobe and 150 ml 0.9% saline was
instilled in three 50 ml aliquots. The BAL fluid was aspirated
and placed immediately on ice until processing. Arterial
blood was collected simultaneously into lithium heparin
tubes (Becton Dickinson) and stored on ice until processing.
Sample processing
The chilled BAL fluid was filtered through a single layer of
coarse surgical gauze to remove clumps of mucus and then
spun at 500g for 5 minutes to pellet the cells. The BAL fluid
supernatant was collected and stored at 280 C˚ until analysis.
A cell count was performed using a haemocytometer and cells
were processed for RNA extraction. RNA was extracted from
BAL cells using the RNesay mini kit according to the
manufacturer’s instructions (Qiagen, UK). RNA was quanti-
fied at 260 nm using a UV wavelength spectrophotometer.
Whole blood was spun at 500g for 10 minutes, the plasma
was removed and stored at 280 C˚ until analysis.
Bioactive VEGF and sVEGFR-1 measurement
Commercially available ELISA kits were used to measure
bioactive VEGF (a bioactive assay detecting free 121 and 165;
Quantikine R&D Systems, UK), total VEGF (Chemicron,
USA) and sVEGFR-1 (Bendermedics, Germany) according to
the manufacturers’ instructions.
VEGF recovery from BAL fluid
BAL fluid from patients with detectable (n=12) and
undetectable (n=12) sVEGFR-1 were spiked with 200 pg/
ml VEGF-A (R&D Systems) for 30 minutes. Bioactive VEGF
was measured by ELISA and the percentage of bioactive
VEGF recovery was calculated.
ELF and protein determination
The urea concentration was determined using a commercially
available urea kit (Sigma Diagnostics). The volume of ELF
was estimated using the formula: ELF volume (l) = BAL
urea (mmol/l)/plasma urea concentration (mmol/l).21 BAL
fluid protein was measured using the Lowry method.22 The
protein permeability index was calculated as plasma protein/
BAL protein6 100.23
BAL cell culture
BAL cells were cultured for 24 hours in RPMI at a
concentration of 16106/ml in the presence of 1 ng/ml tumour
necrosis factor a (TNFa), 1 mg/ml lipopolysaccharide (LPS),
or control media (RPMI). Supernatants were collected and
the concentration of sVEGFR-1 was measured by ELISA.
sVEGFR-1 RT-PCR
sVEGFR-1 and the housekeeping control gene GAPDH were
amplified by RT-PCR. Primers were synthesised (Alta
Bioscience, UK). PCR products were analysed by running
through a 3% (w/v) agarose gel stained with ethidium
bromide (Sigma). Bands were visualised by UVP transillu-
minator and analysed using the ScionImage software
package (ScionImage Corp, USA). The sVEGFR-1 band was
sequenced and confirmed as specific for the soluble and not
membrane associated receptor.
Statistical analysis
The presence or absence of detectable sVEGFR-1 between
patients with ARDS, those at risk, and normal patient groups
were analysed using Fisher’s exact test. Linear relations
between bioactive VEGF, total VEGF, detectable sVEGFR-1,
and severity markers (Murray lung injury score, P:F ratio,
APACHE II, SAPS II) were tested using Pearson’s correlation
coefficient on log transformed data. Data on differences
between receptor positive and receptor negative groups were
of a non-normal distribution and were analysed using the
Mann-Whitney U test. Data on differences between ELF and
plasma sVEGFR-1 were normally distributed and analysed
using the paired sample t test. Normality testing was
performed using the Shapiro-Wilk test. Data are expressed
as median and interquartile range (IQR) or mean (SD).
Where a statistically significant difference is present, the
mean/median difference and 95% confidence interval (95%
CI) is presented. Data analysis was performed using SPSS
10.0 for Windows. A p value of ,0.05 was considered
significant.
RESULTS
Demographic characteristics of patients
Bronchoalveolar lavage was performed in 41 patients within
48 hours of the onset of ALI/ARDS and a repeat broncho-
scopy was performed in 17 patients 4 days after the onset of
ARDS. Bioactive VEGF data alone from seven of the patients
has been reported previously.10 Twelve patients at risk of
ARDS and 16 normal volunteers were recruited as controls.
The factors predisposing the ‘‘at risk’’ group to ARDS were
sepsis (n=7), trauma (n=1), and pneumonia (n=4). Three
of the ‘‘at risk’’ patients had pneumonia and a P:F ratio of
,40 kPa but only unilateral infiltrates on the chest radio-
graph. Lavage was performed on the contralateral side to the
infiltrates in these patients. Detailed demographic character-
istics of the patients are shown in table 1. The mean age of
the normal volunteers was 62 (range 25–77).
sVEGFR-1 in ELF of ARDS patients
sVEGFR-1 was detectable in the BAL fluid of 48% (20/41) of
patients with ALI/ARDS on day 1 (0–48 hours) (ELF
concentration range 1.4–54.8 ng/ml) compared with 8%
154 Perkins, Roberts, McAuley, et al
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(1/12) at risk patients (p=0.017) and none (0/16) of the
normal controls (p=0.002). By day 4 sVEGFR-1 was
detectable in only two out of 18 patients in the ARDS group
(p=0.008, fig 1). In ARDS patients with detectable sVEGFR-
1 on day 1 there was a positive correlation with the P:F ratio
(r=0.466, p=0.038) and a negative correlation with LIS
(r=20.430, p=0.058). There were no linear relations with
APACHE II or SAPS II scores. The survival of ARDS patients
with or without detectable sVEGFR-1 on day 1 was similar in
both groups (R negative 52.4%; R positive 50%).
Total and bioactive VEGF levels in ELF
Total VEGF levels in ELF were higher than bioactive VEGF
levels at day 1 in all groups (table 2). There was a trend
towards lower total VEGF levels in the ELF of ARDS patients
(163.7 ng/ml) compared with at risk subjects (439.1 ng/ml,
p=0.07) and normal controls (234.9 ng/ml, p=0.41). Total
ELF levels of VEGF in ARDS patients on day 1 were
associated with the APACHE II score (r=20.624, p=0.01)
and the SAPS II score (r=20.554, p=0.026). There was an
inverse correlation between total VEGF and protein perme-
ability (r=20.675, p=0.023). No difference was found in
total ELF levels of VEGF on days 1 or 4 and patient survival.
Consistent with our previous findings,10 ELF levels of
bioactive VEGF were lower in ARDS patients than in those at
risk or normal subjects (table 2). There was a moderate
inverse correlation between LIS and bioactive VEGF levels
(r=20.44, p=0.01). The protein permeability index showed
an inverse correlation with bioactive VEGF levels (r=20.59,
p=0.07). There was no difference in ELF levels of bioactive
VEGF on days 1 or 4 and survival.
ARDS subjects with detectable sVEGFR-1 in ELF had lower
median (IQR) levels of bioactive VEGF (1415.2 (474.9–
3192.5) pg/ml) than those with no detectable receptor (4761
(1349.9–7596.6) pg/ml; median difference 3003.9 (95% CI
305.1 to 4711.9), fig 2). There were no linear associations
between levels of total or bioactive VEGF and total sVEGFR-
1. There was a moderate positive correlation between total
VEGF and the ratio between bioactive VEGF and sVEGR-1
(r=0.6; p=0.04).
Relationship with total VEGF to sVEGFR-1 ratio
There was no association between the ratio of total VEGF to
sVEGFR-1 and the LIS (r=0.215, p=0.1). There were
significant inverse relationships between the ratio of total
VEGF to sVEGFR-1 and the protein permeability index
(r=20.625, p=0.04), APACHE II score (r=20.6,
p=0.01), and the SAPS II score (r=20.6, p=0.016).
There was a non-significant relationship between bioactive
VEGF and the ratio of total VEGF to sVEGFR-1(r=0.44,
p=0.1). There was no difference in the ratio of total VEGF to
sVEGFR-1 between survivors and non-survivors.
Plasma levels of sVEGFR-1 in patients with ARDS
Mean (SD) ELF concentrations of sVEGFR-1 (8.9 (9.6) ng/
ml) were higher than plasma concentrations (0.30 (0.58) ng/
ml) in patients with ARDS (p=0.001, 95% CI of difference
Table 1 Demographic characteristics of patients (according to GOCA stratification24)
ARDS
(n = 41)
At risk
(n = 12) p value
Gas exchange
Mean (SD) P:F ratio (kPa) 16.8 (8.2) 39.9 (10.4) 0.001
PaO2/FIO2 .40 kPa 0 9
PaO2/FIO2 26.8–40 kPa 14 2 0.001
PaO2/FIO2 13.46–26.8 kPa 18 1
PaO2/FIO2 ,13.46 kPa 9 0
Spontaneous breathing, no PEEP 0 0
Assisted breathing, PEEP 0–5 cm H2O 14 8 NS
Assisted breathing, PEEP 6–10 cm H2O 18 2
Assisted breathing, PEEP .10 cm H2O 9 1
Organ failure (non-pulmonary)
0 organ 2 2
1 organ 22 6 NS
2 organs 14 2
3 organs 3 0
Cause
Unknown 0 0
Indirect lung injury 17 8 NS
Direct lung injury 24 4
Other parameters
Age 62 (18–93) 68 (29–78) NS
APACHE II 22.1 (9.3) 21.23 (12.2) NS
SAPS II 42.6 (15.8) 42.8 (14.3) NS
LIS 2.7 (0.6) 1.15 (0.7) 0.01
Mortality 51% 46% NS
PEEP, positive end expiratory pressure; APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute
respiratory distress syndrome; LIS, lung injury score; SAPS, Simplified Acute Physiology Score.
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Figure 1 sVEGFR-1 levels in the epithelial lining fluid of patients with
ARDS.
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3.9 to 13.5 ng/ml, fig 3). No sVEGFR-1 was detected in the
plasma of normal volunteers.
Production of sVEGFR-1 by BAL cells and effect of
TNFa
sVEGFR-1 was detected in the BAL fluid supernatants
(n=10) after culture for 24 hours in RPMI (median 1.2
(IQR 0.87–1.61) ng/ml). The concentration of sVEGFR-1
increased following incubation with TNFa to 1.83 (1.41–
2.28) ng/ml, median difference 0.65 (95% CI 0.05 to 1.256),
p=0.044) but not in the presence of LPS (0.98 (0.63–1.38),
p=0.48).
Expression of mRNA for sVEGFR-1 in BAL cells
After finding sVEGFR-1 protein in the BAL fluid super-
natants, we looked to see if mRNA for sVEGFR-1 was
produced by BAL cells using RT-PCR. sVEGR-1 expression
was found in BAL cells from normal subjects, those at risk for
ARDS, and ARDS patients (n=14, fig 4). The expression was
calculated as a percentage of the housekeeping gene GAPDH
to standardise the samples; a range of 31–399% (mean (SE)
166 (23)%) of GAPDH was found, indicating a heterogeneous
population. We therefore split the patients into ARDS (n=5),
patients at risk of ARDS (n=4) and normal subjects (n=5).
The highest mRNA level was found in patients with ARDS
(mean (SE) 162 (60)%) compared with the normal group (86
(13)%) and at risk patients (97 (25)%), p=0.1.
Exogenous VEGF in BAL fluid
Recovery of VEGF spiked into BAL fluid was significantly
reduced in BAL fluid from patients with ARDS (recovery 80.1
(20.5)%, p,0.001). Samples with detectable sVEGFR-1 had
lower VEGF recovery than those with none detectable (72.1%
v 89.3% (95% CI of difference 11.4 to 69.2), p=0.039; fig 5).
DISCUSSION
ARDS is characterised by intense inflammation in the
alveolar space and the development of a high permeability
pulmonary oedema. We initially reported increased levels of
bioactive VEGF, a potent endothelial permeability factor, in
the plasma of patients with ARDS and postulated that VEGF
was likely to play a prominent role in the development of
non-cardiogenic pulmonary oedema.6 Paradoxically, we10 and
others11 have subsequently found reduced levels of bioactive
VEGF in the ELF of patients with ARDS. In the present study
the finding of sVEGFR-1, a naturally occurring antagonist to
VEGF bioactivity, in the ELF of patients with ARDS suggests
a potential mechanism through which the bioactivity of
VEGF may be regulated early in its course.
Shortly after the initial descriptions of inflammatory
cytokines in the alveolar space in ARDS, specific and non-
specific cytokine antagonists that limit the biological effects
of proinflammatory cytokines were discovered. It soon
became clear that the net inflammatory balance was of
greater physiological and clinical importance than individual
cytokine concentrations.13 25 The tight regulation of the
bioavailability of VEGF may be an important factor in the
pathophysiology of ARDS. In adult mice transfection with an
adenovirus vector containing VEGF 165 led to an increase in
the expression of VEGF with a consequential increase in
pulmonary capillary permeability and alveolar oedema.
However, pretreatment of the mice with an adenovirus
vector expressing a truncated soluble form of sVEGFR-1
abrogated completely the development of alveolar oedema in
vivo, demonstrating the ability of sVEGFR-1 to effectively
inhibit the function of excess VEGF.26 We have shown in vitro
that plasma from human subjects with ARDS increases
human pulmonary artery endothelial cell monolayer perme-
ability by nearly 50% compared with control plasma. This
effect was abolished by the addition of recombinant sVEGFR-
1 to the plasma of ARDS patients.6 It is therefore clear that
pulmonary sVEGFR-1 expression early in the course of ARDS
may be a physiological response to limit functional increases
in the permeability of the alveolar-capillary barrier induced
by VEGF.
The novel finding of 50–100 fold higher total VEGF
compared with bioactive VEGF in the ELF of patients with
Table 2 Total and bioactive VEGF levels in epithelial lining fluid (ELF)
Group
Median (IQR) total VEGF
(ng/ml)
Median (IQR) bioactive VEGF
(ng/ml)
Median difference
(95% CI)
Normal 234.9* (160.6–359.2) 6.52 (3.50–9.73) 228.38 (158.6 to 349.6)
At risk 439.1* (322.7–550.2) 5.01 (2.69–8.55) 434.1 (317.8 to 562.7)
ARDS 163.7* (77.9–353.8) 2.68 (0.82–5.90) 161.02 (107.4 to 259.6)
*p,0.001 v ELF levels of bioactive VEGF.
p,0.05 v ELF levels of bioactive VEGF in at risk and normal subjects.
Bioactive VEGF levels were lower in ARDS patients with detectable sVEGFR-1 in BAL fluid but there was no
difference in total VEGF levels.
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Figure 2 Levels of bioactive VEGF in the epithelial lining fluid (ELF) of
patients with and without detectable sVEGFR-1 in BAL fluid.
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Figure 3 sVEGFR-1 levels in the epithelial lining fluid (ELF) and plasma
of patients with ARDS.
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ARDS supports our hypothesis that regulation of the
bioactivity of VEGF is important in ARDS. The presence of
sVEGFR-1 in the ELF of patients with ARDS provides one
potential explanation for reduced bioactive VEGF in this
patient group. This is supported by the spiking experiments
with BAL fluid and VEGF and our finding of a positive
correlation between total VEGF and the ratio of bioactive
VEGF to total sVEGFR-1. However, only half our patients
with ARDS had detectable soluble receptor in the ELF and
VEGF recovery was incomplete even in BAL fluid from
patients with no detectable sVEGFR-1. One potential
explanation could be that the lower limit of detection for
the sVEGFR-1 ELISA we used was 80 pg/ml. Consequently,
we cannot be sure that the soluble receptor was not present
at lower concentrations in our group designated receptor
negative.
The local production of sVEGFR-1 in tissues with high
VEGF levels has also been reported in placental tissue and
primary breast cancer where the ratio of tissue sVEGFR-1 to
VEGF has been identified as an independent predictor of
outcome.27 In parallel with this observation, the findings in
the present study of significant correlations between the ratio
of sVEGFR-1 to total VEGF and disease severity indices
supports our hypothesis that sVEGFR-1 may be important in
regulating the biological function of VEGF in ARDS. The
finding of mRNA and sVEGFR-1 protein from BAL cell
supernatants demonstrates one source for alveolar sVEGFR-1
production in ARDS. This is consistent with our finding of
increased levels of sVEGFR-1 in ELF compared with plasma.
This apparent compartmentalisation of sVEGFR-1 within the
lung may be important for the local regulation of bioactive
VEGF since ELF levels of VEGF are also several times higher
in the lung than in plasma.
The disappearance of the soluble receptor from the ELF in
all but two patients by day 4 of ARDS suggests that the
upregulation of sVEGFR-1 is limited to the early phases of the
condition. This is consistent with our previous finding that
bioactive VEGF levels tended to increase in resolving lung
injury by day 4.10 These changes may be important since
several studies have recently suggested a beneficial role for
VEGF in tissue repair and proliferation. Ohwada has shown
that VEGF can restore the ability of acid injured A549 cells
(human alveolar cell line) to proliferate.12 In animal models
of emphysema, blocking the function of VEGF has been
shown to result in an increase in markers of oxidative stress,
alveolar enlargement, and alveolar cell apoptosis.28 29 VEGF
also plays an important role in maintaining endothelial cell
survival in vitro and in vivo.30 The early downregulation of
sVEGFR-1 and the increase in bioactive VEGF may therefore
be important for alveolar repair after the initial inflammatory
insult. In the present study the number of patients who
underwent sequential lavage did not allow us to explore this
hypothesis further.
We have not ruled out the possibility that other mechan-
isms may operate in parallel with sVEGFR-1 production to
reduce bioactive VEGF in the lung. There may be other
inhibitors to VEGF bioactivity within the lung. ADAMTS1, an
extracellular matrix protease, has been shown to inhibit
VEGF function by reversibly binding with VEGF and blocking
VEGFR-2 phosphorylation leading to the suppression of
endothelial cell proliferation in vitro.31 Connective tissue
growth factor (CTGF) also inhibits VEGF165 binding to
VEGFR-2 in vitro by 30% and reduced the angiogenic effects
of VEGF165 in an in vivo mouse angiogenesis model.
32
Increased VEGF degradation could also explain low levels
of VEGF in ELF. Bhattacharjee et al have recently shown that
a2-macroglobulin, an important proteinase inhibitor, can
bind to VEGF resulting in an increase in receptor mediated
internalisation and degradation via the a2-macroglobulin
receptors on macrophages.33 Although a2-macroglobulin is
usually confined to the intravascular compartment, break-
down of the alveolar capillary barrier leads to extravasation
of this protein into the alveolar space in ARDS23 where it
could potentially stimulate an increase in VEGF degradation.
In our initial study10 we hypothesised that the paradox of
high plasma VEGF levels but low alveolar levels of VEGF in
ARDS could be explained by the loss of VEGF compartmen-
talisation in the lung due to breakdown of the alveolar
capillary barrier. In the present study we investigated the
protein permeability index and found an inverse correlation
with bioactive VEGF levels. This supports the hypothesis that
the increased alveolar-capillary permeability found in ARDS
may contribute to the loss of VEGF compartmentalisation
within the lung. It is thus possible that the activity and
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Figure 4 (A) Expression of mRNA for sVEGFR-1 in BAL cells. (A) Lane
1, molecular weight marker (1 kB); lane 2, normal; lane 3, normal; lane
4, at risk; lane 5, at risk; lane 6, ARDS; lane 7, ARDS; lane 8, negative
control. (B) mRNA levels in BAL cells from patients with ARDS, those at
risk of ARDS and normal subjects.
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function of VEGF within the lung is modulated through
several different and independent pathways.
In conclusion, this study has shown a new mechanism for
the reduced bioactive levels of VEGF seen in patients with
ARDS. sVEGFR-1 levels are higher in the ELF than in plasma
in patients with ARDS, suggesting that there is an intrapul-
monary source of sVEGFR-1. We also found that BAL cells
from patients with ARDS expressed mRNA and produced
protein for the receptor, and would appear to be a source for
the soluble receptor within the lung. Further research into
the source, regulation, and effects of sVEGFR-1 in ARDS is
required. It is as yet unclear whether pulmonary sVEGFR-1
expression is the mechanism for reduced bioactive VEGF
levels seen in other lung diseases associated with epithelial
damage.
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